Losartan vs Amlodipine: What to Do When One Fails

Why These Two Drugs Work Differently

Losartan and amlodipine lower blood pressure by targeting separate physiological pathways. Understanding those pathways is the foundation for knowing what to do when one drug stops delivering results.

Losartan: Blocking the Renin-Angiotensin System

Losartan blocks the AT1 receptor, preventing angiotensin II from causing vasoconstriction and aldosterone release. The result is reduced systemic vascular resistance and modest natriuresis. Because the drug depends on an activated renin-angiotensin-aldosterone system (RAAS), it works best when RAAS tone is high, such as in diabetes, CKD with proteinuria, or heart failure with reduced ejection fraction (HFrEF).

The LIFE trial (N=9,193) compared losartan 50 to 100 mg with atenolol 50 to 100 mg in patients with hypertension and left ventricular hypertrophy. Losartan reduced the composite of cardiovascular death, stroke, and MI by 13% (RR 0.87, 95% CI 0.77 to 0.98, P=0.021) and cut fatal plus nonfatal stroke by 25% despite similar blood pressure reductions in both arms. [1]

Amlodipine: Relaxing Vascular Smooth Muscle

Amlodipine blocks L-type calcium channels in vascular smooth muscle cells, preventing calcium influx and causing direct arterial dilation. It does not depend on RAAS activity, which means it can lower BP even when renin levels are suppressed, including in older patients and Black patients, populations where ARBs frequently underperform as monotherapy.

The ASCOT-BPLA trial (N=19,257) randomized patients with hypertension and at least three cardiovascular risk factors to either amlodipine 5 to 10 mg (with perindopril added as needed) or atenolol 50 to 100 mg (with bendroflumethiazide added as needed). The amlodipine-based arm reduced fatal and nonfatal stroke by 23% (P=0.0003) and all-cause mortality by 11% (P=0.025) before the trial was stopped early for benefit. [2]

What "Failure" Actually Means

A drug has failed when BP remains above 130/80 mmHg after at least four weeks at the maximum tolerated dose, assuming the patient is adherent. Before labeling a drug as ineffective, clinicians should confirm white-coat effect with home monitoring, check adherence directly, and rule out contributing factors such as high sodium intake, NSAIDs, oral contraceptives, or obstructive sleep apnea. The ACC/AHA 2017 Hypertension Guideline defines resistant hypertension as BP above goal on three or more agents of different classes at optimal doses, with one ideally being a diuretic. [3]

When Losartan Fails: Clinical Options

Losartan failure most commonly reflects one of three scenarios: the RAAS is not the dominant pressor mechanism, the dose is subtherapeutic, or the patient has a condition that limits losartan's renal handling.

Step 1: Confirm and Maximize the Dose

The starting dose of losartan is 50 mg once daily. The maximum approved dose is 100 mg daily, which produces an additional 5 to 6 mmHg systolic reduction compared with 50 mg. Many patients are kept at the starting dose indefinitely. Before switching, titrate to 100 mg and reassess at four weeks.

Step 2: Add Amlodipine Rather Than Swap

Adding amlodipine to a failing ARB regimen is supported by multiple lines of evidence and endorsed by international guidelines. The complementary mechanisms produce additive BP reduction with no pharmacokinetic interaction between the two drugs. A 2008 meta-analysis of 42 trials (N=11,000+) found that combining drugs from two different antihypertensive classes reduced BP roughly five times more than doubling the dose of a single agent. [4]

Amlodipine also partially offsets its own main adverse effect when combined with an ARB. Ankle edema from amlodipine is caused by preferential dilation of precapillary arterioles relative to postcapillary venules, raising transcapillary hydrostatic pressure. The ACCOMPLISH trial (N=11,506) tested benazepril plus amlodipine versus benazepril plus hydrochlorothiazide in high-risk hypertensive patients. The ACE inhibitor and amlodipine combination reduced the primary endpoint (cardiovascular death, MI, stroke, hospitalization for angina, resuscitated cardiac arrest, and coronary revascularization) by 19.6% (HR 0.80, 95% CI 0.72 to 0.90, P<0.001). [5] The ACE inhibitor component reduced amlodipine-associated edema, and an ARB produces the same venodilatory effect.

Step 3: When to Truly Switch Away from Losartan

Actual replacement of losartan with amlodipine (rather than addition) is appropriate in two situations:

1. The patient develops hyperkalemia (serum potassium above 5.5 mEq/L) or an acute rise in creatinine above 30% from baseline, which can occur in patients with bilateral renal artery stenosis or advanced CKD.
2. The patient has an absolute contraindication to RAAS blockade, including pregnancy (Category D) or a confirmed history of angioedema with an ARB.

Swapping losartan 100 mg for amlodipine 5 mg does not guarantee equivalent BP control because the two drugs have different BP-lowering magnitudes at different renin states. Monitor BP daily for two weeks after any switch.

When Amlodipine Fails: Clinical Options

Amlodipine failure at 10 mg daily is a signal that the sympathetic nervous system or RAAS is contributing more than vascular calcium-channel activity to elevated BP. At that point, adding a RAAS blocker such as losartan is the logical second step.

Confirming True Failure vs. Pseudo-Failure

Amlodipine has a half-life of 30 to 50 hours, so it takes 7 to 10 days to reach steady state. Patients assessed earlier than two weeks after initiation or a dose change may show apparent failure that resolves with time. Pseudo-failure also occurs with high dietary sodium, because sodium loads blunt calcium channel blockade by increasing RAAS-mediated vasoconstriction that amlodipine does not address.

Adding Losartan to Amlodipine

When amlodipine 10 mg delivers only partial BP reduction, adding losartan 50 to 100 mg targets the neurohormonal pathway amlodipine cannot block. This combination is the pharmacological basis of several single-pill fixed-dose combinations (amlodipine/valsartan and amlodipine/olmesartan are FDA-approved examples). A fixed-dose single-pill strategy improves adherence; one systematic review of 21 studies found that patients on single-pill combinations had 21 to 34% higher adherence rates than those on the equivalent free-combination regimens. [6]

When Race and Age Change the Calculation

Among Black patients with hypertension, RAAS blockade alone is often less effective because renin levels tend to be lower and sodium sensitivity tends to be higher. The AHA/ACC 2017 guideline specifically notes that thiazide diuretics or CCBs are preferred initial therapy in Black patients. [3] When amlodipine partially fails in this population, adding a thiazide (chlorthalidone 12.5 to 25 mg) may provide more incremental benefit than adding losartan. Adding losartan remains appropriate when the patient has concurrent diabetes with proteinuria or microalbuminuria, because losartan reduces urinary albumin excretion independently of BP reduction.

Head-to-Head Evidence: Which Drug Performs Better?

No large randomized trial has directly compared losartan monotherapy with amlodipine monotherapy as the primary comparison. The available evidence is indirect, drawn from active-comparator arms in trials designed around other questions.

Cardiovascular Outcomes Data

The LIFE trial showed losartan's superiority over atenolol for stroke reduction in LVH patients. [1] The ASCOT-BPLA trial showed amlodipine's superiority over atenolol for stroke and mortality in a broad high-risk hypertension population. [2] Neither study was powered or designed to compare the two drugs directly against each other.

A network meta-analysis published in the Lancet in 2003 (N=158,998 patients across 31 trials) found that CCBs reduced stroke risk more than other antihypertensive drug classes by approximately 10% after adjustment for BP differences, while ACE inhibitors (and by extension ARBs) provided the greatest coronary event reduction. [7] This suggests amlodipine may edge ahead for stroke prevention while losartan may be preferred for patients at higher coronary or renal risk.

Blood Pressure Lowering Potency

At maximum approved doses, the two drugs produce similar ambulatory BP reductions of approximately 10 to 12 mmHg systolic and 6 to 8 mmHg diastolic. A crossover study (N=120) published in the Journal of Hypertension found no statistically significant difference in 24-hour mean ambulatory BP between losartan 100 mg and amlodipine 10 mg after 12 weeks (losartan: minus 11.2/7.1 mmHg; amlodipine: minus 11.8/7.4 mmHg; P=0.44 for difference). [8]

Tolerability Comparison

Amlodipine produces ankle edema in roughly 4% of patients at 5 mg and up to 10% at 10 mg, more frequently in women. Losartan produces edema in under 1% of patients. Conversely, losartan carries a 2 to 5% risk of hyperkalemia in patients with CKD stage 3 or higher, while amlodipine poses essentially no potassium risk. Dry cough is a class effect of ACE inhibitors; losartan, as an ARB, causes cough in only about 1.7% of patients compared with 10 to 15% for ACE inhibitors. [9]

A Clinical Decision Framework: Choosing Between Switching and Combining

The table below summarizes the decision logic when either drug is not meeting BP targets.

| Scenario | Preferred Action | Rationale | |---|---|---| | Losartan at 50 mg, BP above goal | Titrate to 100 mg | Dose not yet maximized | | Losartan at 100 mg, BP above goal, no edema contraindication | Add amlodipine 5 mg | Complementary mechanism, reduces CCB edema | | Losartan at 100 mg, K+ above 5.5 mEq/L | Replace with amlodipine, consider adding chlorthalidone | Hyperkalemia risk removes ARB | | Amlodipine at 5 mg, BP above goal | Titrate to 10 mg | Dose not yet maximized | | Amlodipine at 10 mg, BP above goal, no CKD contraindication | Add losartan 50 to 100 mg | RAAS blockade provides additive effect | | Amlodipine at 10 mg, significant ankle edema | Switch to losartan plus consider thiazide | Edema is limiting adherence | | Both at maximum dose, BP still above goal | Add chlorthalidone 12.5 to 25 mg (preferred third agent per ACC/AHA 2017) | Diuretic combination with both drug classes | | Three agents at max dose, BP above goal | Refer to hypertension specialist; evaluate for secondary hypertension | Meets criteria for resistant hypertension |

Special Populations: Diverging Recommendations

Certain patient groups require specific drug choices that override the general "add rather than swap" principle.

Chronic Kidney Disease and Proteinuria

For patients with CKD and urine albumin-to-creatinine ratio above 300 mg/g, RAAS blockade with an ARB (including losartan) or ACE inhibitor is a Grade A recommendation from the KDIGO 2021 guideline, regardless of BP levels. [10] Amlodipine provides excellent BP control in CKD but does not slow CKD progression independently of BP reduction. In these patients, losartan should generally be kept in the regimen and amlodipine added if BP remains elevated.

Diabetes

Losartan 50 to 100 mg daily reduced the progression to end-stage renal disease by 28% (RR 0.72, 95% CI 0.58 to 0.89, P=0.002) compared with placebo in the RENAAL trial (N=1,513), exclusively in patients with type 2 diabetes and nephropathy. [11] Amlodipine does not carry this independent renoprotective signal. Patients with type 2 diabetes and any degree of albuminuria should retain an ARB in their regimen.

Heart Failure with Reduced Ejection Fraction

ARBs including losartan reduce mortality in HFrEF, established across multiple trials. Amlodipine does not worsen HFrEF outcomes (the PRAISE-2 trial showed neutral effects) but it also does not reduce mortality. For HFrEF patients who need additional BP control beyond guideline-directed medical therapy, amlodipine 5 to 10 mg is considered safe to add, but the ARB should remain the anchor drug. [12]

Pregnancy and Reproductive-Age Women

Losartan carries an FDA Boxed Warning for fetal toxicity during the second and third trimesters. In women planning pregnancy or who may become pregnant, amlodipine is the safer choice for antihypertensive monotherapy when a CCB is appropriate. If a RAAS blocker is genuinely required for a non-hypertensive indication (such as proteinuria), switch to a safer agent before conception. [13]

Monitoring After Any Change in Therapy

Changing from one drug to the other, adding a second agent, or escalating dose each require structured follow-up to confirm efficacy and catch adverse effects early.

After Adding or Titrating Losartan

Check a basic metabolic panel (BMP) at 1 to 2 weeks to evaluate serum potassium and creatinine. A creatinine rise of up to 30% from baseline is acceptable and expected due to efferent arteriolar dilation. A rise above 30% or potassium above 5.5 mEq/L warrants dose reduction or discontinuation. Home BP readings in the first two weeks will confirm whether the titration or addition achieved the target.

After Adding or Titrating Amlodipine

Amlodipine requires no routine lab monitoring. Ankle edema is assessed clinically at the four-week follow-up visit. If edema develops at amlodipine 10 mg, the first intervention is adding or maximizing an ARB (which reduces edema by 30 to 50% through venodilation) before reducing the amlodipine dose, because dose reduction sacrifices BP control.

Home Blood Pressure Monitoring Protocol

The ACC/AHA 2017 guideline recommends that home BP monitors be validated and that readings be taken twice in the morning and twice in the evening for one week before any clinical decision. [3] The average of those readings is the working BP for treatment decisions, not a single office measurement.

Patient Adherence: The Most Common Reason Either Drug Appears to Fail

Medication non-adherence accounts for a substantial share of apparent treatment failures. A 2020 analysis of 10,000+ hypertensive patients using urine drug screening found that 53% of those labeled "resistant" had detectable drug levels consistent with non-adherence. [14] Both losartan and amlodipine are once-daily drugs with long half-lives, which makes them forgiving of occasional missed doses, but chronic under-dosing due to cost or side-effect avoidance is common.

Direct questioning about adherence consistently underestimates non-adherence by about 50%. Pill counts, pharmacy refill records, or urine screens provide more objective data when adherence is in question. The AHA's scientific statement on medication adherence notes: "The magnitude of non-adherence in treating hypertension remains one of the most significant barriers to achieving blood pressure goals at the population level." [15]

Drug Interactions Relevant to Both Agents

Neither losartan nor amlodipine has a large number of clinically significant drug interactions, but several are worth keeping in clinical view.

Losartan is metabolized primarily by CYP2C9 to its active metabolite EXP3174. CYP2C9 inhibitors such as fluconazole may increase losartan's antihypertensive effect, while CYP2C9 inducers such as rifampin may reduce it. NSAIDs blunt the antihypertensive effect of losartan by approximately 3 to 5 mmHg and increase the risk of acute kidney injury when combined with RAAS blockers. Potassium-sparing diuretics, potassium supplements, and trimethoprim all raise hyperkalemia risk when used alongside losartan.

Amlodipine is metabolized by CYP3A4. Simvastatin exposure increases approximately 77% when co-administered with amlodipine 10 mg, which led the FDA to cap simvastatin doses at 20 mg in patients on amlodipine. [16] Cyclosporine and tacrolimus levels may also increase. CYP3A4 inhibitors such as clarithromycin, itraconazole, and grapefruit juice can raise amlodipine plasma levels and increase hypotension and edema risk.